Life Science Tools in 2026: The Companies Powering Drug Discovery, Biologics and Laboratory Innovation

Life science tools companies supply the instruments, reagents, analytical technologies and manufacturing systems that pharmaceutical and biotechnology companies depend on to develop medicines, study biological systems and manufacture advanced therapies.

Their commercial importance extends beyond laboratory equipment. A single drug-development programme can require cell culture systems, chromatography, mass spectrometry, sequencing, analytical testing and specialised consumables at different stages of development.

For healthcare leaders, investors and suppliers, the key question is which technology categories are generating demand, which companies control critical capabilities, and where customers still face technical or operational gaps.

Downlaod Customized Sample in this Industry: https://www.towardshealthcare.com/download-sample/5089 

The Financial Scale of Leading Life Science Tools Companies

The latest annual results show the scale of the companies supplying research laboratories, pharmaceutical manufacturers and biotechnology developers.

Sources: Thermo Fisher, Danaher, Merck KGaA, Agilent, Sartorius.

Important: These figures cover different business scopes. Thermo Fisher and Danaher include businesses beyond research tools, while the other figures represent specific reporting scopes. They should not be used as a direct ranking of life science tools market share.

What the 2025 Results Reveal About Industry Demand

Revenue growth is only one part of the story. Segment-level performance offers a clearer view of where customers are spending.

The strongest strategic signal is the difference between general laboratory spending and demand linked to biopharmaceutical production.

Merck KGaA’s Process Solutions business grew organically by 10.7% in 2025, while its broader Life Science business grew organically by 4.0%. This suggests stronger momentum in process-related products than in its overall life science portfolio during the year.

That distinction matters to suppliers. Demand for production-critical consumables and process technologies may follow a different pattern from demand for research instruments, which can be affected by laboratory budgets and equipment replacement cycles.

Which Product Categories Matter Most?

Bioprocessing equipment and consumables

Bioprocessing supports the production of vaccines, recombinant proteins, monoclonal antibodies and other biologic medicines. It includes upstream activities such as cell culture and fermentation, as well as downstream purification, filtration and process monitoring.

Sartorius reported €2.87 billion in 2025 sales from Bioprocess Solutions, compared with €673 million from Lab Products & Services. Its results underline the importance of production-focused products within its business.

The opportunity is not limited to large bioreactors. Pharmaceutical manufacturers also need filtration systems, single-use bags, tubing, process sensors, chromatography media and quality-control technologies.

Business opportunity: Suppliers can target specific process steps where manufacturers need reliable supply, validated materials, reduced contamination risk or improved production efficiency.

Chromatography and analytical instruments

Chromatography and mass spectrometry help researchers identify compounds, measure impurities, characterise biological molecules and test product quality.

These technologies are important in drug discovery, process development, pharmaceutical quality control and regulated manufacturing. Agilent’s fiscal 2025 results showed growth in its Life Sciences and Diagnostics Markets segment, supported by pharmaceutical, diagnostics and related analytical businesses.

Business opportunity: Companies can assess demand for specialised columns, reference standards, sample-preparation products, analytical software, instrument servicing and laboratory validation.

For new entrants, specialised consumables or workflow-specific software may provide a more realistic entry point than developing a complete analytical instrument platform.

Genomics and sequencing technologies

Genomics tools support gene sequencing, biomarker discovery, cancer research, rare-disease studies and the development of cell and gene therapies.

The commercial ecosystem includes sequencing instruments, sample-preparation kits, library-preparation reagents, nucleic-acid extraction systems, bioinformatics software and data-storage infrastructure.

The challenge is that instrument performance alone does not determine customer adoption. Laboratories also assess cost per sample, workflow time, reproducibility, data interpretation and compatibility with existing systems.

Business opportunity: Companies can focus on sample preparation, specialised assay development, bioinformatics, workflow automation and services that help laboratories interpret complex biological data.

Cell analysis and advanced cell culture

Cell culture, flow cytometry, microscopy and cell-analysis platforms are used across cancer research, immunology, drug screening, stem-cell studies and biologics development.

As research programmes become more complex, customers require tools that can distinguish cell populations, measure biological responses and produce reproducible results across experiments.

Business opportunity: Specialised reagents, validated cell models, assay-development services and automated imaging workflows can help research organisations address technical limitations without replacing their entire laboratory infrastructure.

Laboratory automation and digital workflows

Automation can reduce repetitive manual work, improve consistency and increase sample throughput. Common applications include liquid handling, sample tracking, automated preparation and integrated laboratory information systems.

However, automation projects often require more than purchasing a robotic platform. Laboratories must integrate instruments, software, sample-handling processes and quality documentation.

Business opportunity: Companies can supply laboratory integration, workflow software, instrument connectivity, calibration, maintenance and application-specific automation rather than competing directly with large instrument manufacturers.

Leading Companies and Their Strategic Positions

The following companies are relevant competitors and potential partners across the life science tools ecosystem.

This is a capability-based company comparison, not a verified global market-share ranking. Individual companies compete in overlapping but different product categories.

Where Pharmaceutical and Biotechnology Customers Still Face Gaps

For buyers, the biggest challenge is often not the absence of laboratory tools. It is making those tools work reliably across an entire research or production process.

High operating costs: Instruments may require substantial upfront investment, specialised staff, maintenance and recurring consumables. Buyers need to evaluate total cost of ownership rather than instrument price alone.

Workflow incompatibility: Instruments and software from different vendors may not integrate easily, creating manual work, data-transfer problems and additional validation requirements.

Reproducibility and data quality: Inconsistent reagents, sample preparation or instrument performance can undermine experimental results. Quality controls and reliable suppliers are critical.

Bioprocess scale-up: A process that works at laboratory scale may behave differently at pilot or commercial scale. Companies need tools and services that support process development, monitoring and validation.

Service and supply reliability: Instrument downtime or shortages of specialised consumables can delay research programmes and manufacturing schedules.

Data management: Genomics, high-content imaging and advanced analytical instruments can generate large datasets. Laboratories need secure storage, compatible software and workflows that support interpretation and traceability.

These gaps create opportunities for suppliers that can demonstrate measurable improvements in reliability, workflow efficiency, data quality or manufacturing performance.

Business Opportunities for Emerging Companies and Suppliers

Develop specialised consumables

Consumables are often purchased repeatedly and may be tied to established laboratory workflows. Examples include assay kits, filtration products, sample-preparation materials and specialised reagents.

Entry requires product consistency, clear performance evidence and appropriate quality documentation. Customers may be reluctant to change suppliers if a new product introduces risk to validated workflows.

Provide contract services and technical support

Instrument calibration, maintenance, analytical testing, method development and laboratory validation can support customers that lack the necessary internal capacity.

Companies can build expertise around specific technologies or regulated applications rather than trying to offer every laboratory service.

Target biologics manufacturing requirements

Single-use technologies, filtration, process monitoring and analytical services are important to biopharmaceutical production.

Suppliers should assess the qualification requirements of manufacturers, including material compatibility, extractables and leachables, contamination control, documentation and supply continuity.

Build software around existing instruments

Laboratories may already have suitable equipment but struggle with fragmented data, manual workflows and poor instrument connectivity.

Software that supports sample tracking, data integration, quality documentation and automated reporting can address these problems without requiring laboratories to replace their entire instrument base.

Identify licensing and acquisition targets

Established tool companies can use partnerships and acquisitions to access new assays, specialist reagents, software or proprietary technologies.

Potential targets should be assessed by technical differentiation, intellectual property, validation evidence, customer adoption and compatibility with the buyer’s existing distribution network.

What Healthcare Leaders Should Evaluate Before Investing

Before entering a product category or expanding a supplier portfolio, decision-makers should evaluate:

• Customer concentration: Determine whether revenue depends on a few large pharmaceutical accounts or is spread across research, clinical and industrial customers.

• Recurring revenue: Measure the contribution from consumables, service contracts and repeat purchases versus one-time instrument sales.

• Technical differentiation: Assess whether the product offers a demonstrable improvement in sensitivity, throughput, reproducibility, cost or workflow integration.

• Regulatory and quality requirements: Establish which quality systems, validation procedures and product-specific requirements apply to the intended customer base.

• Switching costs: Understand whether customers can change suppliers easily or must repeat validation and qualification work.

• Manufacturing and supply risks: Evaluate specialised raw materials, supplier concentration, production capacity and delivery reliability.

• Commercial fit: Identify the right buyers, application areas, distribution partners and geographic priorities.

The objective is to find product categories where technical capability, customer need and commercial viability align.

How Towards Healthcare Supports Life Science Tools Companies

Towards Healthcare provides strategic intelligence to help businesses evaluate competitors, identify customers and assess opportunities across life science technologies.

Its services include:

• Life Science Tools Master Dataset: Structured company, product and technology intelligence.

• Competitive Quadrant: Comparison of competitors by capabilities, portfolio and strategic position.

• Customized intelligence dashboards: Tracking of companies, technologies, product categories and industry developments.

• Buyer Identification: Identification of pharmaceutical, biotechnology, laboratory and manufacturing customers.

• Partnership Intelligence: Assessment of potential suppliers, technology partners and acquisition targets.

• Go-to-Market Strategy: Support for product prioritisation, geographic expansion and commercial planning.

For life science tools businesses, the central question is not simply which technologies are growing. It is which customer problems remain unresolved, which companies are best positioned to solve them, and where a new product or partnership can create measurable commercial value.

About Us

Healthcare Web Wire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram